←
ModeX Therapeutics74 posts
ModeX Therapeutics avatar

ModeX Therapeutics

@ModeXTx

We are shaping a new and better way to make transformational medicines a reality for people in need. ModeX is an OPKO Health company (Nasdaq: OPK).

◷ Joined November 2022▧ 61 Photos and videos
ModeX Therapeutics avatar
ModeX Therapeutics@ModeXTx·Mar 30

ModeX’s Dr. John Mascola will be at World Vaccine Congress 2026 to discuss the development of unique tetravalent antibodies for COVID and influenza highlighting ModeX’s work in this area. If you are at the Congress, drop in and join the conversation. @jrmascola

Post attachment
ModeX Therapeutics avatar
ModeX Therapeutics@ModeXTx·29 Oct 2025

We are excited to announce we have initiated Phase 1/2a clinical trial (NCT07110584) with MDX2004, a first-in-class trispecific antibody-fusion protein for oncology and immune disorders. See here for more bit.ly/436FmEW $OPK #multispecifics #antibodies

BiotechTV avatar
⟳ ModeX Therapeutics retweeted
BiotechTV@BiotechTV·29 Jul 2025

𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰 𝐍𝐢𝐠𝐡𝐭: From Boston, former NIH Director Elias Zerhouni will discuss with BiotechTV the current political and policy environment, and how it is affecting science.

Post attachment
ModeX Therapeutics avatar
ModeX Therapeutics@ModeXTx·6 Dec 2024

Excited to share that Dr. Ronnie Wei, Head of Biologics Discovery and Development, appeared on the @Lonza Podcast to answer questions on what antibodies are, how they are made, and why development in this space has accelerated rapidly. Listen here: bit.ly/41mZsul $OPK

ModeX Therapeutics avatar
ModeX Therapeutics@ModeXTx·7 Nov 2024

ModeX is excited to share information about MDX2001, a novel tetraspecific T cell engager for treatment of advanced solid tumors, at #SITC24 on Nov. 8. Stop by our posters in the Exhibit Hall to learn more. Details found here: bit.ly/40r06qj Tags: $OPK

Post attachment
ModeX Therapeutics avatar
ModeX Therapeutics@ModeXTx·14 Oct 2024

Want to know more about what we do? Check out our latest publication in Science Translational Medicine, where we show the potential of multispecific antibodies against #COVID-19. Read more here: science.org/doi/10.1126/scit…

ModeX Therapeutics avatar
ModeX Therapeutics@ModeXTx·8 Mar 2024

Happy International Women's Day! Today we celebrate each of the incredible women at ModeX for their commitment to advancing science and creating new medicines. We're grateful to be able to empower each other on our path to making a difference for patients together. #IWD24

Post attachment
ModeX Therapeutics avatar
ModeX Therapeutics@ModeXTx·5 Mar 2024

Today we announced results from a Phase 1 clinical study of SAR441236, a trispecific antibody for the treatment and prevention of #HIV, at the 2024 Conference on Retroviruses and Opportunistic Infections (#CROI). Learn more: bit.ly/4c2Jzw3

Post attachment
ModeX Therapeutics avatar
ModeX Therapeutics@ModeXTx·23 Feb 2024

By combining multiple antigen-binding sites into a single molecule, our multispecific antibodies are as space-efficient as they can be. Our MSTAR platform simplifies gene expression, allowing for more efficient manufacturing & gene-based antibody delivery. bit.ly/3FOQRoe

0:08
ModeX Therapeutics avatar
ModeX Therapeutics@ModeXTx·8 Feb 2024

Did you know that the HIV virus is one of the most genetically diverse pathogens? Our multispecific HIV antibody, derived from our MSTAR platform, has the potential to potently target more HIV strains than any monospecific antibody. Learn more: bit.ly/3FOQRoe

0:23